Loading people...
Jorge Becerril is a Partner of Public Equity at Novo Holdings US, a global life sciences investment firm based in San Francisco, California. Prior to joining the venture capital organization in 2021, he served as the Executive Director of Corporate Development at Global Blood Therapeutics, where he was responsible for leading strategic biotechnology partnerships and executing complex licensing transactions. His earlier corporate background includes business development roles at Portola Pharmaceuticals, as well as advisory work as a life sciences management consultant at LEK Consulting. Academically, he earned a doctorate in Organic Chemistry from Yale University and subsequently completed postdoctoral research focused on diversity oriented chemical synthesis at Boston University. Becerril currently combines his deep scientific training and corporate transaction experience to evaluate and manage public equity investments across the broader biotechnology and healthcare therapeutics sectors.
Jorge Becerril is a distinguished Principal at Novo Ventures, a prominent venture capital firm dedicated to investing in the life sciences sector. In this pivotal role, Jorge plays a crucial part in the firm's strategic investment activities, focusing on identifying and nurturing groundbreaking companies that are poised to make a significant impact on global health.
Novo Ventures is renowned for its deep expertise and extensive network within the life sciences industry, and Jorge Becerril's contributions align perfectly with the firm's mission. His investment focus areas typically encompass a broad spectrum of the life sciences, including cutting-edge biotechnology, transformative medical technology, and innovative digital health solutions. He is actively involved in evaluating potential investments, conducting due diligence, and providing ongoing strategic support to portfolio companies, helping them navigate complex development pathways and achieve their commercial objectives. His work supports the advancement of new therapies, diagnostics, and healthcare delivery models that address unmet medical needs.
While specific details of Jorge Becerril's career background are not publicly detailed, his position as a Principal at Novo Ventures suggests a robust professional history in venture capital, corporate development, or a related field within the life sciences. Professionals in such roles often bring a blend of scientific understanding, business acumen, and financial expertise, honed through years of experience in the pharmaceutical, biotech, or medical device industries, or through prior roles in investment banking or consulting focused on healthcare. This background equips him with the critical insights needed to assess the scientific merit, market potential, and operational viability of early-stage and growth-stage life science companies.
As part of the Novo Ventures team, Jorge Becerril contributes to the firm's impressive portfolio of companies that are developing next-generation treatments and technologies. While individual notable investments are typically attributed to the firm as a whole, Jorge's involvement is key to the success of many of these ventures, from initial investment to strategic exits or further funding rounds. His dedication helps drive innovation and brings vital capital and expertise to companies striving to improve patient outcomes worldwide. Jorge Becerril is a key figure in Novo Ventures' ongoing commitment to shaping the future of healthcare through strategic investment.
Jorge Becerril is a Principal at Novo Ventures, a leading venture capital firm specializing in life sciences investments. He plays a key role in identifying and supporting innovative companies within the biotech, medtech, and digital health sectors.
Jorge Becerril, through his role at Novo Ventures, invests in companies across the life sciences industry. His focus areas include biotechnology, medical technology, and digital health solutions that aim to advance healthcare and address unmet medical needs.
Jorge Becerril works as a Principal at Novo Ventures. Novo Ventures is a prominent venture capital firm dedicated to investing in the life sciences sector globally.
